Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1

Nature Genetics

Volumn 37, Issue 10, 2005, Pages 1055-1062

  Park, Yeong Gwan ^a,c   Zhao, Xiaohong ^a   Lesueur, Fabienne ^b,d   Lowy, Douglas R ^a   Lancaster, Mindy ^a   Pharoah, Paul ^b   Qian, Xiaolan ^a   Hunter, Kent W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c Korea Intellectual Property Office   (South Korea)

^d CNRG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; BREAST TUMOR; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE; GENE CONTROL; GENE EXPRESSION; GENE LOCUS; GENE OVEREXPRESSION; METASTASIS; METASTASIS EFFICIENCY MODIFIER LOCUS 1; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SIGNAL INDUCED PROLIFERATION ASSOCIATED GENE 1; SIGNAL TRANSDUCTION;

ANIMALS; BIOLOGICAL ASSAY; CELL ADHESION; CERCOPITHECUS AETHIOPS; COS CELLS; GTPASE-ACTIVATING PROTEINS; HUMANS; MICE; MUTATION; NEOPLASM METASTASIS; NUCLEAR PROTEINS; POLYMORPHISM, GENETIC; RAP GTP-BINDING PROTEINS; RNA, SMALL INTERFERING; TRANS-ACTIVATION (GENETICS);

ANIMALIA;

EID: 25844511053     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng1635     Document Type: Article

References (49)

1. Liotta, L.A. & Stetler-Stevenson, W.G. Principles of Molecular Cell Biology of Cancer: Cancer Metastasis, 134-149 (J.B. Lippincott Co., Philadelphia, 1993).
2. Heimann, R., Lan, F., McBride, R. & Hellman, S. Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin. Cancer Res. 60, 298-304 (2000).
3. Guy, C.T., Cardiff, R.D. & Muller, W.J. Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12, 954-961 (1992).
4. Lifsted, T. et al. Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int. J. Cancer 77, 640-644 (1998).
5. Hunter, K.W. et al. Predisposition to efficient mammary tumor metastatic progression is linked to the breast cancer metastasis suppressor gene Brms1. Cancer Res. 61, 8866-8872 (2001).
6. Seraj, M.J., Samant, R.S., Verderame, M.F. & Welch, D.R. Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res. 60, 2764-2769 (2000).
7. Park, Y.G. et al. Comparative sequence analysis in eight inbred strains of the metastasis modifier QTL candidate gene Brms1. Mamm. Genome 13, 289-292 (2002).
8. Hitzemann, R. et al. Multiple cross mapping (MCM) markedly improves the localization of a QTL for ethanol-induced activation. Genes Brain Behav. 1, 214-222 (2002).
9. Wiltshire, T. et al. Genome-wide single-nucleotide polymorphism analysis defines haplotype patterns in mouse. Proc. Natl. Acad. Sci. USA 100, 3380-3385 (2003).
10. Park, Y.G., Clifford, R., Buetow, K.H. & Hunter, K.W. Multiple cross and inbred strain haplotype mapping of complex-trait candidate genes. Genome Res. 13, 118-121 (2003).
11. Tsukamoto, N., Hattori, M., Yang, H., Bos, J.L. & Minato, N. Rap1 GTPase-activating protein SPA-1 negatively regulates cell adhesion. J. Biol. Chem. 274, 18463-18469 (1999).
12. Hitzemann, R. et al. A strategy for the integration of QTL, gene expression, and sequence analyses. Mamm. Genome 14, 733-747 (2003).
13. Steeg, P.S. Metastasis suppressors alter the signal transduction of cancer cells. Nat. Rev. Cancer 3, 55-63 (2003).
14. Bois, P. et al. Isolation and characterization of mouse minisatellites. Genomics 50, 317-330 (1998).
15. Nakamura, Y., Koyama, K. & Matsushima, M. VNTR (variable number of tandem repeat) sequences as transcriptional, translational, or functional regulators. J. Hum. Genet. 43, 149-152 (1998).
16. Bailly, S., Israel, N., Fay, M., Gougerot-Pocidalo, M.A. & Duff, G.W. An intronic polymorphic repeat sequence modulates interleukin-1 alpha gene regulation. Mol. Immunol. 33, 999-1006 (1996).
17. van Ham, M. & Hendriks, W. PDZ domains-glue and guide. Mol. Biol. Rep. 30, 69-82 (2003).
18. Hogue, C.W. Cn3D: a new generation of three-dimensional molecular structure viewer. Trends Biochem. Sci. 22, 314-316 (1997).
19. Altschul, S.F. et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25, 3389-3402 (1997).
20. Kurachi, H. et al. Human SPA-1 gene product selectively expressed in lymphoid tissues is a specific GTPase-activating protein for Rap1 and Rap2. Segregate expression profiles from a rap1GAP gene product. J. Biol. Chem. 272, 28081-28088 (1997).
21. Noda, Y. et al. Aquaporin-2 trafficking is regulated by PDZ-domain containing protein SPA-1. FEBS Lett. 568, 139-145 (2004).
22. Pei, X.F. et al. Explant-cell culture of primary mammary tumors from MMTV-c-Myc transgenic mice. In Vitro Cell. Dev. Biol. Anim. 40, 14-21 (2004).
23. Gao, Q., Srinivasan, S., Boyer, S.N., Wazer, D.E. & Band, V. The E6 oncoproteins of high-risk papillomaviruses bind to a novel putative GAP protein, E6TP1, and target it for degradation. Mol. Cell. Biol. 19, 733-744 (1999).
24. Gould, K.A. et al. Genetic evaluation of candidate genes for the Mom1 modifier of intestinal neoplasia in mice. Genetics 144, 1777-1785 (1996).
25. Sledz, C.A., Holko, M., de Veer, M.J., Silverman, R.H. & Williams, B.R. Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 5, 834-839 (2003).
26. Snove, O., Jr. & Holen, T. Many commonly used siRNAs risk off-target activity. Biochem. Biophys. Res. Commun. 319, 256-263 (2004).
27. Dhanasekaran, S.M. et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412, 822-826 (2001).
28. LaTulippe, E. et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 62, 4499-4506 (2002).
29. Bhattacharjee, A. et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl. Acad. Sci. USA 98, 13790-13795 (2001).
30. Garber, M.E. et al. Diversity of gene expression in adenocarcinoma of the lung. Proc. Natl. Acad. Sci. USA 98, 13784-13789 (2001).
31. Ramaswamy, S., Ross, K.N., Lander, E.S. & Golub, T.R. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33, 49-54 (2003).
32. Miele, M.E. et al. Metastasis suppressed, but tumorigenicity and local invasiveness unaffected, in the human melanoma cell line MelJuSo after introduction of human chromosomes 1 or 6. Mol. Carcinog. 15, 284-299 (1996).
33. Sekita, N. et al. Epigenetic regulation of the KAI1 metastasis suppressor gene in human prostate cancer cell lines. Jpn. J. Cancer Res. 92, 947-951 (2001).
34. Khanna, C. & Hunter, K. Modeling metastasis in vivo. Carcinogenesis 26, 513-523 (2005).
35. Pharoah, P.D. et al. Polygenic susceptibility to breast cancer and implications for prevention. Nat. Genet. 31, 33-36 (2002).
36. Day, N. et al. EPIC-Norfolk: study design and characteristics of the cohort. European prospective investigation of cancer. Br. J. Cancer 80 Suppl 1, 95-103 (1999).
37. Hattori, M. et al. Molecular cloning of a novel mitogen-inducible nuclear protein with a Ran GTPase-activating domain that affects cell cycle progression. Mol. Cell. Biol. 15, 552-560 (1995).
38. Ohba, Y. et al. Requirement for C3G-dependent Rap1 activation for cell adhesion and embryogenesis. EMBO J. 20, 3333-3341 (2001).
39. Yajnik, V. et al. DOCK4, a GTPase activator, is disrupted during tumorigenesis. Cell 112, 673-684 (2003).
40. Seftor, E.A. et al. Molecular determinants of human uveal melanoma invasion and metastasis. Clin. Exp. Metastasis 19, 233-246 (2002).
41. Stork, P.J. Does Rap1 deserve a bad Rap? Trends Biochem. Sci. 28, 267-275 (2003).
42. Farina, A. et al. Bromodomain protein Brd4 binds to GTPase-activating SPA-1, modulating its activity and subcellular localization. Mol. Cell. Biol. 24, 9059-9069 (2004).
43. Ishida, D. et al. Myeloproliferative stem cell disorders by deregulated Rap1 activation in SPA-1-deficient mice. Cancer Cell 4, 55-65 (2003).
44. Hunter, K., Welch, D.R. & Liu, E.T. Genetic background is an important determinant of metastatic potential. Nat. Genet. 34, 23-24 (2003).
45. Hunter, K.W. Allelic diversity in the host genetic background may be an important determinant in tumor metastatic dissemination. Cancer Lett. 200, 97-105 (2003).
46. Hunter, K.W. Host genetics and tumour metastasis. Br. J. Cancer 90, 752-755 (2004).
47. Gordon, D., Abajian, C. & Green, P. Consed: a graphical tool for sequence finishing. Genome Res. 8, 195-202 (1998).
48. Le Voyer, T. et al. An epistatic interaction controls the latency of a transgene-induced mammary tumor. Mamm. Genome 11, 883-889 (2000).
49. Hedenfalk, I. et al. Gene-expression profiles in hereditary breast cancer. N. Engl. J. Med. 344, 539-548 (2001).